NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Alto Marketing Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cresset Introduces New Generation of Cloud Computing Applications with FieldStere V2.0 - Cresset announce the release of a new version of its FieldStere bioisostere generator
Cresset Introduces New Generation of Cloud Computing Applications with FieldStere V2.0

 

NewswireTODAY - /newswire/ - Welwyn Garden City , Herts, United Kingdom, 2010/03/12 - Cresset announce the release of a new version of its FieldStere bioisostere generator.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cresset today announced the release of a new version of its FieldStere bioisostere generator. FieldStere delivers shorter lead optimization cycles to computational and medicinal chemists by enabling them to choose the best syntheses, to fine-tune portions of lead molecules and to scaffold hop to expand into new areas of chemical space.

FieldStere V2.0 is the first in Cresset’s new generation of ‘cloud enabled’ applications, which support parallel, distributed computing by default. This brings real-time assessment of new directions for medicinal chemistry, as well as the patentability and in-licensing potential of drug candidates, a step closer. FieldStere can also be run as a traditional desktop application, allowing users without a large computing infrastructure to benefit from the same functionality.

“By re-engineering the FieldStere concept, we have made it easier to deploy in a corporate distributed computing or workflow environment, as well as making it faster, more memory efficient and more accurate” commented Tim Cheeseright, Products Director at Cresset.

FieldStere V2.0 introduces more flexible licensing and new features to improve productivity. A command line interface supports scripting and workflow systems, while FieldStere databases now have automatic fragment de-duplication and time-stamping to support results tracking in ELN & patent applications. New ‘Bio-Isostere Factor’ scores help to clearly differentiate the effect of replacement moieties, and potentially unstable chemistries are now automatically highlighted in the results table. FieldStere also enables results to be exported as PDFs and copied in 2D or 3D for pasting into drawing applications or presentations.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Alto Marketing Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cresset Introduces New Generation of Cloud Computing Applications with FieldStere V2.0

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Leigh Dilley - Alto-Marketing.com 
+44(0)14 8955 7672 leighd[.]alto-marketing.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Alto Marketing Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)